LivaNova (NASDAQ:LIVN) Updates FY25 Earnings Guidance

LivaNova (NASDAQ:LIVN) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of $3.65-3.75 for the period, compared to the consensus estimate of $3.66. The company issued revenue guidance of ~$1.316-1.329 billion, compared to the consensus revenue estimate of $1.33 billion. LivaNova also updated its FY 2025 guidance to 3.650-3.750 EPS.

LivaNova Price Performance

Shares of LivaNova stock traded down $0.02 during trading hours on Wednesday, reaching $41.68. 250,823 shares of the company’s stock were exchanged, compared to its average volume of 530,955. LivaNova has a 1 year low of $40.37 and a 1 year high of $64.47. The company has a market capitalization of $2.26 billion, a P/E ratio of 99.13 and a beta of 1.00. The business has a fifty day moving average of $47.78 and a two-hundred day moving average of $49.62. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46.

Wall Street Analysts Forecast Growth

LIVN has been the subject of a number of research reports. Needham & Company LLC dropped their target price on shares of LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a report on Wednesday. Mizuho dropped their target price on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. Wolfe Research lowered shares of LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday. StockNews.com raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Friday, February 14th. Finally, Stifel Nicolaus dropped their price objective on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday. Two analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $65.33.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 1,250 shares of the company’s stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now owns 7,522 shares of the company’s stock, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 0.27% of the stock is currently owned by insiders.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.